Logo Image
Opinion|Videos|December 30, 2024

Administering Bispecifics in the Community vs Academic Centers

Key Takeaways

  • Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
  • Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
SHOW MORE

Panelists discuss understanding the comparative advantages, decision-making factors, infrastructure requirements, and partnership models for administering bispecific antibodies in community vs academic settings, with particular focus on patient care logistics and referral pathways.

Episodes in this series

Video content above is prompted by the following

  • What are the benefits of administering bispecific antibodies in the community setting compared with tertiary centers?
  • What factors might influence the decision to administer these agents at an academic center instead of in a community setting?
  • What kind of infrastructure is needed to administer these agents in the community setting that poses key challenges?
  • How are you partnering with academic or community centers to support these patients? What is your internal referral pathway?

Related to this article

View more
Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?
Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Read more